← Eichor
Study identifier: NCT07046559 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants

Condition: Healthy · Cancer  ·  Sponsor: Eli Lilly and Company

PhasePhase 1
Planned participants104
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.

This description comes directly from the study's public registry record.

Talk to the study team

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or  ·  1-317-615-4559  ·  LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact  ·  clinical_inquiry_hub@lilly.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fortrea Clinical Research UnitHolbeck, Leeds, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07046559